WENBIT - Western Norway B Vitamin Intervention Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

3,096

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

June 30, 2007

Study Completion Date

February 29, 2008

Conditions
Coronary Artery DiseaseMyocardial InfarctionCerebrovascular Stroke
Interventions
DRUG

folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)

folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day

DRUG

folic acid, vitamin B12 (cyanocobalamin)

folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day

DRUG

vitamin B6 (pyridoxine)

vitamin B6 40 mg, in a capsule, taken orally once a day

DRUG

placebo

placebo, in a capsule, taken orally once a day

Trial Locations (2)

4011

Department of Cardiology, Stavanger University Hospital, Stavanger

5021

Department of Heart Disease, Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

collaborator

Norwegian Foundation for Health and Rehabilitation

OTHER

collaborator

Norwegian Heart and Lung Patient Organisation

UNKNOWN

collaborator

The Royal Norwegian Ministry of Health

OTHER

collaborator

Locus for Homocysteine and Related Vitamins, University of Bergen, Norway

OTHER

collaborator

Locus for Cardiac Research, University of Bergen, Norway

OTHER

collaborator

Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway

OTHER

collaborator

Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

INDUSTRY

lead

Haukeland University Hospital

OTHER